HealthcarefromLos Angeles Times6 days agoEli Lilly slashes obesity drug price by up to 20%Eli Lilly cut cash-pay prices for lower-dose Zepbound vials to $299 and $399 to compete with Novo Nordisk and expand obesity treatment access.